254 related articles for article (PubMed ID: 28242136)
1. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.
Perico L; Mandalà M; Schieppati A; Carrara C; Rizzo P; Conti S; Longaretti L; Benigni A; Remuzzi G
Am J Kidney Dis; 2017 Jul; 70(1):145-150. PubMed ID: 28242136
[TBL] [Abstract][Full Text] [Related]
2. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
4. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
5. Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.
Flaherty DC; Hoffner BW; Lau BJ; Hamid O; Faries MB
J Surg Oncol; 2015 Dec; 112(8):844-5. PubMed ID: 26503563
[TBL] [Abstract][Full Text] [Related]
6. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
7. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
8. A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma.
Lee le M; Feun L; Tan Y
Am J Case Rep; 2014 Oct; 15():441-3. PubMed ID: 25305754
[TBL] [Abstract][Full Text] [Related]
9. Dabrafenib- and trametinib-associated glomerular toxicity: A case report.
Jo E; Rhee H
Medicine (Baltimore); 2022 Jan; 101(1):e28485. PubMed ID: 35029901
[TBL] [Abstract][Full Text] [Related]
10. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
[TBL] [Abstract][Full Text] [Related]
11. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
[TBL] [Abstract][Full Text] [Related]
12. Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.
Nardin C; Colas M; Badoz M; Roche-Kubler B; Meneveau N; Puzenat E; Aubin F
Eur Heart J; 2017 Jul; 38(27):2151. PubMed ID: 28329154
[No Abstract] [Full Text] [Related]
13. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
14. Bilateral Ischemic Retinal Vasculitis in Metastatic Cutaneous Melanoma Patient Treated with Dabrafenib and Trametinib: A Case Report.
Niro A; Recchimurzo N; Sborgia A; Guida M; Alessio G
Ocul Immunol Inflamm; 2018; 26(5):783-785. PubMed ID: 27973971
[No Abstract] [Full Text] [Related]
15. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
[TBL] [Abstract][Full Text] [Related]
17. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
[TBL] [Abstract][Full Text] [Related]
18. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.
Sundaram VR; Abbas T
Medicine (Baltimore); 2018 Nov; 97(44):e12751. PubMed ID: 30383630
[TBL] [Abstract][Full Text] [Related]
19. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.
Atkinson V; Long GV; Menzies AM; McArthur G; Carlino MS; Millward M; Roberts-Thomson R; Brady B; Kefford R; Haydon A; Cebon J
Asia Pac J Clin Oncol; 2016 Dec; 12 Suppl 7():5-12. PubMed ID: 27905182
[TBL] [Abstract][Full Text] [Related]
20. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]